<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304105</url>
  </required_header>
  <id_info>
    <org_study_id>LF-CA-PR-8</org_study_id>
    <nct_id>NCT04304105</nct_id>
  </id_info>
  <brief_title>Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study</brief_title>
  <official_title>Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LimFlow, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LimFlow, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this observational registry is to track the clinical progression of chronic
      limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization
      attempts over a one-year period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Amputation Free Survival (AFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as freedom from major (above ankle) amputation and death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minor Amputation</measure>
    <time_frame>12 months</time_frame>
    <description>Below-ankle, amputation of digit(s) or above of the index limb</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is comprised of Rutherford 5 and 6 CLTI subjects who have hemodynamic
        evidence of severely diminished arterial inflow of a peripheral limb and:

          1. 2 revascularizations in the last 6 months that failed to resolve symptoms, OR

          2. have inadequate popliteal, tibial, or pedal revascularization target
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be â‰¥18 years of age

          2. Subject is Rutherford 5 or 6 classification with hemodynamic evidence of severely
             diminished arterial inflow of a peripheral limb and: a) 2 revascularizations in the
             last 6 months that failed to resolve symptoms, OR b) An inadequate popliteal, tibial,
             or pedal revascularization target

          3. Subject is willing and able to sign the informed consent form and willing to
             participate in the phone follow-ups.

        Exclusion Criteria:

          1. Any significant concurrent psychological or social condition (e.g., no support
             person/network), which may significantly interfere with the subject's optimal
             participation in the study, in the opinion of the investigator.

          2. Subject is participating in the PROMISE II Clinical Trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Molly Sentell</last_name>
    <phone>(888) 478-7705</phone>
    <email>msentell@limflow.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marlys Chellew</last_name>
    <email>mchellew@chellewclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Knight</last_name>
      <phone>352-375-1212</phone>
      <phone_ext>1324</phone_ext>
      <email>sknight@tcavi.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

